ISOMORPHIC LABS, an AI drug discovery platform released from Google’s deep sea in 2021, raised its external capital for the first time. The $ 600 million rounds said that Thrive Capital was led by GV’s participation and the parent alphabet of existing investors.
This fund will accelerate the further development of a homogeneous AI drug design engine and support the company’s goals that bring the discovered drugs to clinical trials.
The homophobia laboratory was established by DEMIS HASABIS, the co -founder of Deepmind, using the Software of the DEEPMIND for the discovery of AI drugs, including the AI model, which predicts the three -dimensional structure of the protein.
Last year, the homogeneous laboratory secured a strategic partnership with ELI LILLY and NOVARTIS, creating up to $ 3 billion of milestones for access to the AI model.
Hassabis said the new York Times did not require capital, but additional funds would help the department to hire the top research scientists.
He was one of the three scientists who won the Chemical Award in 2024 on their research on Alphafold, Hassabis and DEEPMIND Researcher John Jumper.
